MRI-Guided Procedure Software for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests new software that assists doctors in using MRI images to guide needles during cancer procedures, such as biopsies or ablations. The goal is to determine if this software, called Philips Interventional iSuite, enables doctors to place needles more easily and quickly compared to standard MRI methods. It suits patients already scheduled for a procedure involving MRI-guided needle placement. This trial could result in more precise and efficient cancer treatments. As an unphased trial, it offers patients the chance to contribute to innovative research that could improve future cancer care.
Do I need to stop my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications.
What prior data suggests that this MRI-guided procedure software is safe for use in cancer treatments?
Research shows no specific safety data currently available for the Philips Interventional iSuite software. This software assists doctors in guiding needles during procedures like biopsies (taking a small tissue sample for testing) and ablations (removing unhealthy tissue).
The FDA has not yet cleared the Philips Interventional iSuite software, meaning it isn't officially approved for general medical use. However, studies are underway to determine if it can make these procedures more effective and faster for doctors. Since the software only aids in imaging and doesn't directly interact with the patient, it is expected to be generally safe.
Without direct safety data, the trial's "Not Applicable" phase suggests the software is likely considered low risk, as such software typically doesn't have direct physical effects on the body.12345Why are researchers excited about this trial?
Researchers are excited about the MRI-guided procedure software from Philips because it enhances precision during biopsies and ablations. Unlike standard MRI imaging, this advanced software guides needle placement in real-time, potentially improving accuracy and reducing the risk of complications. By integrating this technology into cancer treatment, clinicians hope to streamline procedures, making them safer and more effective for patients.
What evidence suggests that this MRI-guided procedure software is effective for cancer?
This trial will evaluate the Philips Interventional iSuite software, which studies have shown can enhance needle placement precision during MRI-guided procedures. The software provides live images that assist doctors in guiding needles more accurately for biopsies and treatments like tumor removal. By improving accuracy, it may prevent damage to nearby healthy tissues and increase the procedure's effectiveness. Early signs suggest it could make these procedures faster and more reliable than standard MRI methods.14567
Who Is on the Research Team?
David A Woodrum, M.D., Ph.D.
Principal Investigator
Mayo Clinic
Are You a Good Fit for This Trial?
This trial is for patients already scheduled to undergo MR-guided procedures like biopsies or ablations, where needles are inserted through the skin. Pregnant women cannot participate in this study.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
MRI Guided Procedure
Evaluate the workflow and effectiveness of the Philips Interventional iSuite software during biopsies and/or ablations
Follow-up
Participants are monitored for safety and effectiveness after the MRI guided procedure
What Are the Treatments Tested in This Trial?
Interventions
- Philips Interventional iSuite software
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mayo Clinic
Lead Sponsor
Philips Healthcare
Industry Sponsor
Roy Jakobs
Philips Healthcare
Chief Executive Officer since 2022
Master's in Business Administration from Radboud University Nijmegen and Università degli Studi di Bologna
Dr. Roy Jakobs
Philips Healthcare
Chief Medical Officer
MD from McGill University